Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
DO
By Daniel Okafor · Regulatory Correspondent
Oct 25 21:11 ETSource: The Malaysian Reserve
From the source
Read at themalaysianreserve.comAscletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
